StoxSai Life Sciences vs Piramal Pharma: share price & financials comparison
NSE: SAILIFE vs PPLPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Piramal Pharma at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹40,972 Cr, against ₹32,484 Cr for Piramal Pharma (PPLPHARMA). Over the past year Sai Life Sciences has returned +108.9%, compared with +22.0% for Piramal Pharma. Sai Life Sciences earns a higher return on equity (7.5% vs -2.6%). Sai Life Sciences comes out ahead on size, profitability, financial health, momentum and technicals. Piramal Pharma comes out ahead on valuation and growth. Across the scored metrics below, Sai Life Sciences leads on 9 and Piramal Pharma on 2. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Piramal Pharma scores 6/10.
| Metric | Sai Life Sciences | Piramal Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹40,972 Cr | ₹32,484 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹8,869 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹-326 Cr |
| Valuation | ||
| P/E | 202.3 | — |
| P/B | 15.24 | 3.99 |
| Dividend yield | — | 0.06% |
| Profitability | ||
| Return on equity | 7.5% | -2.6% |
| Net profit margin | 8.5% | -2.1% |
| Operating margin | 29.5% | 12.3% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | +28.1% |
| Revenue CAGR (multi-year) | — | +7.8% |
| Financial health | ||
| Debt to equity | 0.17 | 0.70 |
| Momentum | ||
| 1-month return | +31.9% | +24.8% |
| 1-year return | +108.9% | +22.0% |
| 3-year CAGR | — | +26.7% |
| Distance from 52W high | +0.0% | -0.7% |
| Technicals | ||
| RSI (14) | 93 | 86 |
| Price vs 200-day avg | +56.3% | +35.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Piramal Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Piramal Pharma?
Sai Life Sciences has a market cap of ₹40,972 Cr and Piramal Pharma has a market cap of ₹32,484 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Sai Life Sciences or Piramal Pharma?
Sai Life Sciences did better: Sai Life Sciences returned +108.9% and Piramal Pharma returned +22.0% over one year.
What is the difference between Sai Life Sciences and Piramal Pharma?
Both are NSE-listed companies in Healthcare. Sai Life Sciences is about 1.3 times the size of Piramal Pharma by market cap. In the latest financial year Sai Life Sciences reported revenue of ₹2,192 Cr and Piramal Pharma ₹8,869 Cr. Operating margin is 29.5% for Sai Life Sciences and 12.3% for Piramal Pharma. Debt to equity is 0.17 for Sai Life Sciences and 0.70 for Piramal Pharma.
Which is better, Sai Life Sciences or Piramal Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sai Life Sciences leads on 9 and Piramal Pharma on 2. Sai Life Sciences is ahead on size, profitability, financial health, momentum and technicals. Piramal Pharma is ahead on valuation and growth. On StoxGud's rules-based checklist Sai Life Sciences scores 6/10 and Piramal Pharma scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.